FDA warned rxmedkart.com it sells unapproved, misbranded drugs online, including a COVID-19 'Ziverdo Kit.'
What happened
FDA reviewed www.rxmedkart.com on May 12, 2021 and observed it offered drugs for sale in the U.S. to treat COVID-19 and parasitic diseases. FDA cited a 'Ziverdo Kit' (zinc acetate, doxycycline, ivermectin) promoted for COVID-19 without FDA approval, and said the prescription drugs lacked adequate directions for safe lay use, making them misbranded.
What FDA found
FDA says the products are unapproved new drugs sold without an FDA-approved application.
section 505(a), FD&C Act [21 U.S.C. § 355(a)]FDA says the products are misbranded drugs.
section 502, FD&C Act [21 U.S.C. § 352]FDA says introducing or delivering these products into interstate commerce is prohibited.
sections 301(a), 301(d), FD&C Act [21 U.S.C. § 331(a), § 331(d)]FDA says the prescription drugs lack adequate directions for use, so a layperson cannot use them safely.
section 502(f)(1), FD&C Act [21 U.S.C. § 352(f)(1)]; 21 CFR 201.5FDA says the drugs are not exempt from adequate-directions labeling because they are not approved in the U.S.
21 CFR 201.115(a)
What FDA wants
FDA tells the company to stop selling the unapproved and misbranded products and to email FDA within 48 hours with the specific steps taken to correct the violations and prevent recurrence, including supporting documents; if it cannot finish within 48 hours, it must explain the delay and give a completion time.
Who should pay attention
- online pharmacies selling to U.S. consumers
- companies making COVID-19-related drug claims
- buyers or importers of unapproved prescription drugs
This is a summary. Read the original letter on fda.gov.